4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Kuchena >98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory

Tsanangudzo Pfupi:

Zita: 4-Chloro-7-Methoxyquinoline-6-Carboxamide

CAS: 417721-36-9

Kuchena:> 98.5% (HPLC)

Chitarisiko: Off-White kusvika Chiedza Yellow Powder

Pakati peLenvatinib Mesylate CAS 857890-39-2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Tsanangudzo:

Chemical Properties:

Chemical Name 4-Chloro-7-Methoxyquinoline-6-Carboxamide
Mashoko anoreva zvakafanana 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib Kusachena 12;Lenvatinib Kusachena B;Lenvatinib Kusachena LFS-B
Nhamba yeCAS 417721-36-9
Nhamba yeCAT RF-PI1971
Stock Status MuStock, Kugadzira Kugona 50MT/Gore
Molecular Formula C11H9ClN2O2
Molecular Weight 236.65
Melting Point >205 ℃ (Zvita)
Density 1.380±0.060 g/cm3
Brand Ruifu Chemical

Zvinotsanangurwa:

Item Zvinotsanangurwa
Chitarisiko Off-White kusvika Chiedza Yellow Powder
Kuchena / Analysis Method >98.5% (HPLC)
Kurasika paKuomesa <0.50%
Residue paIgnition <0.50%
Zvose Zvisina Kuchena <1.50%
Proton NMR Spectrum Inopindirana neChimiro
Test Standard Enterprise Standard
Usage Pakati peLenvatinib Mesylate (CAS: 857890-39-2)

Package & Kuchengeta:

Package: Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.

Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza uye unyoro

Zvakanakira:

1

FAQ:

Application:

4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) inonyanya kushandiswa sepakati peLenvatinib Mesylate (CAS: 857890-39-2).Yakagadzirwa neEisai Inc., lenvatinib mesylate inonzi vascular endothelial growth factor receptor (VEGF) inhibitor ine chiitiko chinopesana neVEGF subtypes 1, 2, uye 3 uye yakatenderwa neFDA muna 2015 kurapwa kweakasiyaniswa gomarara rethyroid rinowanikwa munharaunda. inodzokororwa, metastatic, kana kufambira mberi uye haina kupindura kune radioactive iodine kurapwa.Muna Chivabvu 2016, FDA yakabvumidza mushonga uyu semusanganiswa wekurapa neeverolimus pakurapa renal cell carcinoma.Nemhaka yokuti VEGF (uye fibroblast growth factor receptors, inozivikanwa seFGFRs) inofungidzirwa kuti inobata basa mumigwagwa yemwoyo yemwoyo, VEGF2R uye FGFR inhibition inofungidzirwa kuti ndiyo nzira dziri shure kwechikamu chekutanga chelenvatinib mesylate, iyo hypertension.

Nyora meseji yako pano uye titumire kwatiri